ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Targeting CML cells with tyrosine kinase inhibitor (TKI) against BCR-ABL can effectively treat the patients in chronic phase, however the single agent does not cure the disease yet [1], 2.